Catalyst Pharmaceutical Inc.
CPRXStock
$31.49+45.65%52W
Market Cap$3.85B
P/E17.99x
Div yield—
Beta0.78
Price Chart
Favorite Metrics
Price vs S&P 500 (26W)30.78%
Price vs S&P 500 (4W)0.78%
VGM Score65.31
Market Capitalization$3.85B
P/E Ratio (Annual)17.99x
Earnings Surprise History
Q1 260.50est. 0.47
Analyst Recommendations
Mar 2026
Apr 2026
May 2026
Jun 2026
4.43
4.43
4.43
3.67
Industry Peers — Pharmaceuticals(563)
| Symbol | Value Score | Growth Score | Momentum Score | Price |
|---|---|---|---|---|
CPRXCatalyst Pharmaceutical Inc. | C | B | B | $31.49 |
| LLYEli Lilly & Co. | D | B | B | $1169.17 |
| JNJJohnson & Johnson | D | C | B | $249.97 |
| ABBVABBVIE INC. | D | C | B | $254.39 |
| MRKMerck & Co., Inc. | C | C | B | $127.63 |
| NVSNovartis AG | C | C | C | $152.73 |
| NVONovo-Nordisk A/S | C | B | C | $51.48 |
| AZNAstraZeneca PLC | C | B | C | $169.29 |
| ABTAbbott Laboratories | C | C | D | $98.83 |
| PFEPfizer Inc. | B | C | C | $25.14 |
| VRTXVertex Pharmaceuticals Inc | D | C | C | $486.03 |
About
Catalyst Pharmaceuticals is a commercial-stage biopharmaceutical company focused on rare and difficult-to-treat diseases. The company commercializes three FDA-approved drugs: FIRDAPSE (amifampridine), AGAMREE (vamorolone), and FYCOMPA (perampanel). It pursues growth through acquiring accretive assets, including clinical-stage candidates with established proof of concept.